Navigation Links
Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
Date:1/27/2011

SARASOTA, Fla., Jan. 27, 2011 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued Notice of Allowances on three patent applications relating to the use of novel monoclonal antibodies for the treatment of hemolytic uremic syndrome (HUS) caused by shiga toxin II secreting E.coli O157: H7 strain.

Lakewood Amedex is the exclusive licensee of the US patents, issued to Tufts University.  Based on work led by Saul Tzipori, BVSc., DSc., PhD, distinguished professor of biomedical sciences at the Cummings School of Veterinary Medicine at Tufts, as well as other members of the school's Division of Infectious Diseases, the patents entitled -- "Humanized Neutralizing Antibodies against Hemolytic Uremic Syndrome" -- are the first patents to be granted in this family and will provide the Company with a strong intellectual property position for treating this serious illness.  HUS is usually associated with E.coli 0157:H7 food poisoning and affects more than 300,000 people worldwide annually.  There is currently no approved therapeutics for the treatment of this condition, which mainly affects young children and the elderly, as well as individuals with compromised immune systems.  The Company is seeking to fast-track development of its lead fully human monoclonal antibody candidate into clinical trials in 2011.

The Company's head scientist, Paul DiTullio, commented "The granting of these three patents will give Lakewood-Amedex a dominant position for the use of monoclonal antibodies to treat this life threatening condition.  Although the initial indication will be for the treatment of hemolytic uremic syndrome, the Company believes the product will have a more expanded usage in preventing the kidney damage caused by shiga toxin in patients suffering from a less severe infection which can lead to a number
'/>"/>

SOURCE Lakewood-Amedex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains
2. Varian Medical Systems Security and Inspection Products Group Receives Largest Single Order for IntellX Systems
3. Crestwood Technology Group Receives Silver Boeing Performance Excellence Award
4. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
5. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
6. Aribex CEO Receives Utah Governors Medal
7. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
8. Mindray Receives its Largest Order of Patients Monitors in Canada
9. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
10. Zyga Technology, Inc. Receives FDA 510(K) Clearance for the SImmetry™ Sacroiliac Joint Fusion System
11. Cambrex Zenara Manufacturing Facility Receives European GMP Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... fiscal third quarter 2015 after the market close on ... will also host a conference call for investors on ... (10:00 a.m. Eastern Time). Investors may access the live ...
(Date:8/3/2015)... and MINNEAPOLIS , ... BSX ) has become a significant shareholder and ... representative for Preventice Solutions for cardiology-related diagnostic and ... an important strategic milestone for Preventice Solutions," said ... Strategy Officer, co CEO, Preventice Solutions.  "We are ...
(Date:8/3/2015)... 3, 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO ... for the quarter ended June 30, 2015. All comparisons, unless ... Second Quarter 2015 Highlights include: ... $266 million , Total prescriptions dispensed of 234,000, an ... 5.5% , Adjusted EBITDA of $22.7 million, an increase ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2Boston Scientific Announces Equity Investment And Sales Cooperation Agreement With Preventice Solutions 2Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... Jennerex,Inc. (San Francisco, CA and Ottawa, Ontario), and ... of the first five patients in a,Phase 2 primary ... JX-594. No significant toxicities were reported, and enrollment of,patients ... The Phase 2 trial involves treatment of patients ...
... Pulmo BioTech Inc. has completed a dual listing. The ... (symbol PBO) in addition to the OTC BB (OTC ... role in the future development and financing of the ... the United States and Canada" - Garry McCann, CEO ...
Cached Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 2Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... analysis for executives and technology professionals in healthcare and technology markets, today announced ... the Department of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related ...
(Date:8/3/2015)... ... August 04, 2015 , ... Approved ... extensive line up of live courses for the month of August. , Physical ... individually or by purchasing a Physical Therapy Flex package. Flex packages allow ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Putnam counties. As a family owned and operated business, Zeiter’s Septic has ... They are a leader in septic installations because of their continued training and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Since 1978, the number ... according to a new publication released today by the AAMC (Association of American Medical ... graduates over the past three decades, the number of black male applicants to medical ...
(Date:8/3/2015)... ... ... According to an opinion piece published July 28 by the Washington Post, the ... weight loss may not be accurate. While this system may work for some people, the ... – based both on the individual and at what point that person is in their ...
Breaking Medicine News(10 mins):Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2
... of Internal Medicine journal, Obese or overweight Chinese individuals ... developing tuberculosis than those at a normal weight. ... undernutrition in both developed and developing countries. In addition, ... a wide range of chronic degenerative conditions, notably, diabetes ...
... University of Washington shows that the work intended for ... economy . ,The research was conducted by a ... Hagopian, professor in the School of Public Health and ... Initiative; and Sally Weatherford, finance and administration director of ...
... guitarist Kevin Eubanks have won the 'World's Sexiest Vegetarians' title at ... new to the title, for she won the tag in 2005 ... for NBC's 'Tonight Show' band leader Eubanks, who bagged votes due ... for the 49-year-old and 'bring honour' to the show. ...
... researchers identify cost-effective treatment for drug-resistant typhoid. Researchers ... may be more effective at treating typhoid fever ... Organisation. ,Enteric fever, of which typhoid fever ... affecting the developing world, where sanitary conditions remain poor. ...
... have found that umbilical cord blood might safely preserve insulin ... ,The study was conducted by a team of ... Florida. ,As part of the study, researchers identified ... their umbilical cord blood at birth, and gave seven patients ...
... study published in the Journal of the National Cancer ... cancers is increasing, but this finding is likely ... Deirdre Cronin-Fenton, Ph.D., of Aarhus University Hospital in Denmark, ... Md., found that the increase in some early stage ...
Cached Medicine News:Health News:Obesity is Related to Lower Tuberculosis Risk 2Health News:Global Health Enriching the States Economy 2Health News:Gatifloxacin Very Effective for Typhoid Treatment 2
... ring pessary, available in nine ... support, is a very common ... second degree prolapse. The Ring ... used on an accompanying cystocele. ...
The Capio CL Transvaginal Suture Capturing Device allows for a transvaginal suture fixation to Cooper's Ligament for sling procedures...
... SPARC™ Sling System utilizes a suprapubic ... incontinence due to urethral hypermobility and/or ... two curved, narrow-diameter needles and a ... suture that allows for intra-operative tension ...
... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
Medicine Products: